Umberto Costantino

Dr. Umberto Costantino


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2026 in Epilepsia Open
Verified
Journal Article
Open access
GDGiuseppe D’Orsi
Giuseppe D’Orsi
ECEzio Calò
Ezio Calò
MCMaria Teresa Di Claudio
Maria Teresa Di Claudio
CFCarmela Pia Ferro
Carmela Pia Ferro
UCUmberto Costantino
Umberto Costantino
RLRaffaela Rita Latino
Raffaela Rita Latino
Objective: Individuals with Down syndrome (DS) face an ultra‐high risk of Alzheimer's disease (AD). Within this continuum, Progressive Myoclonus Epilepsy (PME) has emerged as a marker of advanced neurodegeneration. Building on our 2014 characterization of this syndrome, we aimed to define its long‐term natural history and pathological substrate. Methods: We conducted an 11‐year longitudinal study of the original cohort of 12 DS patients with PME. Clinical progression was monitored via a three‐stage model. Two additional illustrative cases (aged 50 and 58 years) underwent 18F‐Flutemetamol PET to document in vivo amyloid load. Results: The study reached a 100% mortality rate. Median survival from myoclonus onset was 4.2 years (95% CI: 3.8–4.6). All patients progressed to the terminal phase within 2.5 ± 1.1 years. Both Amyloid‐PET‐scanned patients revealed a massive cortical burden (Global Z ‐scores up to 11.55). Iatrogenic clinical worsening due to sodium channel blockers or phenobarbital was observed in 38% of cases. The high uniformity of these findings allowed for the proposal of diagnostic criteria based on a mandatory DS‐AD association, a core clinical triad (myoclonus, ataxia, seizures), and supportive biomarkers. PME‐DS appears to be driven by an amyloid‐related excitatory‐inhibitory imbalance. Massive amyloid‐beta deposition in motor cortices impairs GABAergic interneurons, triggering cortical hyperexcitability. Thus, the onset of myoclonus serves as a functional marker of peak amyloid burden and terminal neurodegeneration. Significance: PME‐DS with AD represents a severe electroclinical phenotype within the AD‐DS continuum, likely overlapping with the widely recognized LOMEDS (Late‐Onset Myoclonic Epilepsy in Down Syndrome). Myoclonus onset serves as a definitive “red flag” of a severe amyloid‐driven excitatory‐inhibitory imbalance and peak cortical burden, predicting rapid progression to terminal stage (median survival 4.2 years). Standardizing the proposed diagnostic criteria is essential for accurate prognostic counseling and, crucially, to avoid iatrogenic pitfalls in pharmacological management, particularly regarding the use of sodium channel blockers. Plain Language Summary: This study followed 12 adults with Down syndrome who developed a severe form of epilepsy linked to Alzheimer's disease. We found that when people with Down syndrome develop jerking movements (myoclonus), it signals advanced brain changes and predicts a rapid decline, with most patients surviving only about 4 years. Brain scans showed a massive buildup of abnormal proteins in the brain. Importantly, certain common seizure medications (like phenytoin and carbamazepine) made symptoms worse in over one‐third of patients. Recognizing this pattern early helps doctors provide better care, avoid harmful medications, and prepare families for what to expect.

24 January 2024 in Brain Disorders
Verified
Journal Article
Open access
UCUmberto Costantino
Umberto Costantino
ETEleonora Torchia
Eleonora Torchia
GGGiuseppe Granata
Giuseppe Granata
AMAnna Modoni
Anna Modoni

28 July 2025 in Epilepsia
Verified
Journal Article
Open access
GDGiuseppe Didato
Giuseppe Didato
FVFederico Vigevano
Federico Vigevano
LTLaura Tassi
Laura Tassi
RGRenzo Guerrini
Renzo Guerrini
MCMarco de Curtis
Marco de Curtis
IGItalian Epilepsy Surgery Collaborative Group
Italian Epilepsy Surgery Collaborative Group
Objective: To study the current practice of epilepsy surgery in Italy and the relative impact of coronavirus disease 2019 (COVID‐19) pandemic on it. Methods: We launched a survey through the Italian National Virtual Epilepsy Institute, to identify centers with epilepsy surgery programs and collect data on the current preoperative and surgical practices. We reported changes in surgical volumes and complications and seizure outcomes between 2018 and 2022, that is, before and after the COVID‐19 pandemic in Italy. Results: A total of 21 of the 26 surveyed centers (80.7%) responded. Eleven centers (52.4%) reported having an established epilepsy surgery program, with most performing complex procedures, such as multilobar, disconnective, and hemispheric interventions. However, only a few carry out minimally invasive surgeries. Presurgical evaluation protocols vary across centers, but in keeping with international standards. Globally, 618 surgeries were performed in children and 621 in adults (total 1239) between 2018 and 2022. The most frequent type of surgery was unilobar extratemporal lobectomy for children (38.7%, p < 0.0001) and unilobar temporal lobectomy for adults (63.3%, p < 0.0001). Hemispheric surgeries were more frequent in children than in adults (11.5% vs 2.1%, p = 0.001), whereas interventions in unrevealing magnetic resonance (MRI) cases were more frequent in adults than in children ( p = 0.030). At the onset of COVID‐19outbreak in Italy (March 2020), we observed a significant decrease in the total number of operations compared to 2019, especially for hemispheric interventions ( p = 0.027). Surgical volumes resumed in 2021, particularly for temporal lobe epilepsies and in adult cohorts. Surgical complications increased significantly in 2020 (Incidence Rate Ratio [IRR] = 13.13), whereas seizure outcome did not change significantly between 2018 and 2022. Significance: Advanced pre‐ and postsurgical evaluation protocols are currently implemented across Italy, with a great variability between centers. Starting in 2021, epilepsy surgery volumes have regained their pre‐pandemic levels, albeit with a slight loss of complexity, whereas seizure outcome has remained stable.

13 April 2026 in Genes
Verified
Journal Article
Open access
PDF file
MBMario Benvenuto
Mario Benvenuto
UCUmberto Costantino
Umberto Costantino
PPPietro Palumbo
Pietro Palumbo
MCMassimo Carella
Massimo Carella
MCMarco Castori
Marco Castori
OPOrazio Palmieri
Orazio Palmieri
Background: Pathogenic variants in the NEXMIF gene have been linked to a broad neurodevelopmental phenotype, encompassing autism spectrum disorder, intellectual disability, and epilepsy. Among epileptic manifestations, Jeavons Syndrome was observed in 24% of affected females in the largest cohort of NEXMIF-related disorders reported to date, but long-term adult outcomes remain poorly documented. Methods and Results: We report a 25-year-old Italian woman with drug-resistant Jeavons syndrome in which the combined approach of next-generation sequencing and chromosomal microarray analysis allowed us to identify, after a 13-year diagnostic odyssey, a de novo ~350 Kb microdeletion at Xq13.2q13.3 encompassing the entire NEXMIF coding region, with no other OMIM genes involved. To our knowledge, this is the first reported case of a patient harboring a deletion restricted to the entire coding sequence of the NEXMIF gene. The patient presented with moderate intellectual disability and seizure onset at age 10 years. Her epilepsy proved refractory to multiple antiseizure medications. Video-EEG/polygraphic monitoring at age 23 years confirmed epilepsy with eyelid myoclonia, demonstrating characteristic eyelid myoclonia with absences triggered by eye closure. Conclutions: This case provides a detailed clinical description of an adult patient useful for genetic counseling regarding adult outcomes and prognostic expectations. Furthermore, this study underscores the diagnostic value of chromosomal microarray analysis alongside next-generation sequencing in individuals with intellectual disability and drug-resistant epilepsy, in order to expedite the diagnostic pathway and enable timelier and more appropriate patient management.

1 August 2026 in Epilepsia Open
Verified
Journal Article
Open access
GDGiuseppe D’ORsi
Giuseppe D’ORsi
UCUmberto Costantino
Umberto Costantino
MCMaria Teresa Di Claudio
Maria Teresa Di Claudio
CFCarmela Pia Ferro
Carmela Pia Ferro
PPPietro Palumbo
Pietro Palumbo
OPOrazio Palumbo
Orazio Palumbo
Objectives: Adults with developmental and epileptic encephalopathies (DEEs) often enter adult neurology care without etiologic clarification because of incomplete transition from pediatric services, outdated investigations, and attenuation of childhood electro‐clinical features over time. We aimed to assess the clinical utility and diagnostic yield of a structured, phenotype‐guided etiologic workup in adults meeting study criteria for DEE and to explore associations between electro‐clinical phenotype and etiologic category. Methods: We prospectively enrolled consecutive adults (≥18 years) with drug‐resistant epilepsy and neurodevelopmental impairment temporally related to epileptic activity, consistent with the ILAE operational definition of DEE, referred to a tertiary epilepsy center between May 2022 and December 2025. Patients underwent a 4‐phase reassessment pathway including critical review of prior documentation, detailed clinical and semiologic phenotyping, prolonged video‐EEG monitoring, phenotype‐guided genetic testing (targeted resequencing, chromosomal microarray), high‐resolution neuroimaging, and multidisciplinary case review to support etiologic clarification and treatment planning. Results: Among 144 patients (mean age 28.4 years; 57.6% male), a confirmed etiology was identified in 91 (63.2%). Genetic causes predominated (65 patients, 45.1%), including monogenic (53, 36.8%) and chromosomal (12, 8.3%) disorders, primarily resolved via targeted resequencing gene panels and via chromosomal microarray analysis respectively, while structural‐metabolic etiologies accounted for 26 cases (18.1%). Lennox–Gastaut syndrome was significantly associated with structural‐metabolic and chromosomal etiologies (69.2% and 58.3% vs. 9.4% in monogenic; p < 0.0001), whereas, excluding patients with a broader Lennox–Gastaut syndrome phenotype, absence seizures occurred exclusively in monogenic cases ( p = 0.024). Etiologic clarification changed clinical management in 27.1% of the cohort, including antiseizure medication optimization/precision therapies (25%) and pre‐surgical referral (2.1%). Significance: In adults with suspected DEE, the practical value of this approach lies not only in diagnostic yield, but in showing that structured adult reassessment remains clinically worthwhile. Electro‐clinical phenotype can help prioritize etiologic testing, and etiologic clarification can support more informed treatment planning and counseling even long after transition from pediatric care. Plain Language Summary: Adults with developmental and epileptic encephalopathy (DEE) often reach adult epilepsy services without a clear diagnosis. In this study, we used a structured approach combining clinical review, video‐EEG, MRI, genetic testing, and multidisciplinary discussion in 144 adults with suspected DEE. We identified a confirmed cause in 63.2% of patients. Genetic causes were the most common, but structural and metabolic causes were also important. Some seizure patterns helped guide diagnosis: Lennox–Gastaut syndrome was more common in structural‐metabolic and chromosomal cases, while absence seizures occurred only in monogenic cases. Identifying the cause also helped guide treatment decisions, including medication changes, targeted therapies, surgery referral, and genetic counseling. This study shows that adults with suspected DEE can still benefit from careful diagnostic reassessment, even years after childhood.

10 March 2025 in Genes
Verified
Journal Article
Open access
PDF file
EMEster Di Muro
Ester Di Muro
PPPietro Palumbo
Pietro Palumbo
MCMassimo Carella
Massimo Carella
MBMario Benvenuto
Mario Benvenuto
MBMaria Rachele Bianchi
Maria Rachele Bianchi
OPOrazio Palmieri
Orazio Palmieri
Background: The GRIN2A gene and its product protein have been linked to a wide spectrum of neurodevelopmental disorders named GRIN2A-related disorders. Clinical presentation is highly variable and characteristically includes acquired cognitive, behavioral, and language impairment, as well as epilepsy, ranging from benign forms to severe epileptic encephalopathy. Recent genetic investigations have expanded the clinical spectrum of heterozygous GRIN2A variants, improving our understanding of genotype–phenotype correlations. However, there have been few long-term observational studies of patients affected by the genetically determined GRIN2A-related disease. Methods: To understand the long-term changes in clinical features, we described three patients from two Italian families, carrying variants in the GRIN2A gene. Results: After more than a decade of extensive electro-clinical follow-up, we observed a progressive cognitive decline associated with severe behavioral disturbances, despite clinical seizure control. The persistent presence of EEG epileptiform abnormalities over time suggests the need for a longitudinal neurophysiological study to monitor disease progression and evaluate the potential for anti-seizure medication discontinuation. Conclusions: Our study offers new insights into the natural progression of epilepsy in GRIN2A-related disorders, highlighting that a more detailed understanding of the phenotype and timely, personalized treatment could enhance the management and quality of life for both GRIN2A patients and their caregivers.